氨在预测慢性心力衰竭中心房动风险方面的价值
Qing-Fen Zhou1, Qiu-Ya Lu2, Yang Dai3
1Department of Cardiovascular Medicine, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Frontiers in cardiovascular medicine
|September 4, 2024
概括
血清氨酸 (Phe) 水平升高与心力衰竭 (HF) 患者的心房动 (AF) 有关. 较高的Phe表明AF风险增加和AF的HF结果较差.
科学领域:
- 生物化学 生物化学
- 心脏病学 心脏病学
- 临床医学 临床医学
背景情况:
- 心房动 (AF) 是慢性心力衰竭 (HF) 的常见并发症.
- 血清氨酸 (Phe) 水平与炎症性疾病有关.
- 在HF患者中研究循环Phe和AF之间的联系是重要的.
研究的目的:
- 确定血清氨酸水平与心力衰竭患者中心房的发生之间的关联.
- 在HF患者中探索氨酸和高灵敏性C反应蛋白 (hsCRP) 之间的关系.
- 评估氨在预测AF的HF患者的不良事件中的预后价值.
主要方法:
- 一项横截面研究包括300名HF患者 (70名AF患者) 和100名对照患者,用液体染色学-并联质谱法测量血清Phe.
- 使用后勤回归分析来评估Phe和AF风险在HF中的关联.
- 在对274名高频受试者的前性随访中,评估了Phe和HF终点事件之间的关联.
主要成果:
- 与那些没有AF和对照组相比,AF的HF患者的血清Phe水平显著更高 (P < 0.001).
- 血清Phe升高是预测HF的AF的一个独立风险因素 (OR,1.640;P = 0.006).
- 费水平与hsCRP正相关 (r = 0.577,P < 0.001),并且与AF患者中HF不良事件的风险更高有关 (P = 0.005).
结论:
- 在心力衰竭患者心房动,氨酸水平升高增加AF预测的风险.
- 较高的氨值与较差的心力衰竭结果有关.
- 血清氨酸可以作为心力衰竭中心房动的一个有价值的生物标志物.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
68
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
68
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352